Intravenous Immunoglobulin Therapy and Systemic Lupus Erythematosus
Authors:
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 29 (3) , 219-228
Abstract
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with diverse manifestations. We suggest that intravenous immunoglobulin (IVIg) therapy may be beneficial and safe for various manifestations in SLE. A structured literature search of articles published on the efficacy of IVIg in the treatment of SLE between 1983 and 2005 was conducted. We searched the terms “IVIg,” “intravenous immunoglobulin,” “lupus,” “SLE,” and “systemic lupus erythematosus.” The various clinical manifestations of SLE that were reported to be successfully treated by IVIg in case reports include autoimmune hemolytic anemia, acquired factor VIII inhibitors, acquired von Willebrand disease, pure red cell aplasia, thrombocytopenia, pancytopenia, myelofibrosis, pneumonitis, pleural effusion, pericarditis, myocarditis, cardiogenic shock, nephritis, end-stage renal disease, encephalitis, neuropsychiatric lupus, psychosis, peripheral neuropathy, polyradiculoneuropathy, and vasculitis. The most extensive experience is with lupus nephritis. There are only a few case series of IVIg use in patients with SLE with various manifestations, in which the response rate to IVIg therapy ranged from 33 to 100%. We suggest that IVIg devoid of sucrose, at a dose of 2 g/kg over a 5-d period given uniformly and at a slow infusion rate in patients without an increased risk for thromboembolic events or renal failure, is a safe and beneficial adjunct therapy for cases of SLE that are resistant to or refuse conventional treatment. The duration of therapy is yet to be established. Controlled trials are warranted.Keywords
This publication has 40 references indexed in Scilit:
- IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patientsAutoimmunity, 2005
- Intravenous immunoglobulins in peripheral neuropathy associated with vasculitisAnnals of the Rheumatic Diseases, 2003
- Immunoglobulin for rheumatic diseases in the twenty-first centuryCurrent Opinion in Rheumatology, 2003
- Pure Red Cell Aplasia as Presentation of Systemic Lupus Erythematosus: Antibodies to Erythropoietin: CASE REPORTScandinavian Journal of Rheumatology, 1999
- Successful treatment of early secondary myelofibrosis in SLE with IVIGLupus, 1997
- Prolonged Remission of SLE-associated Polyradiculoneuropathy after a Single Course of Intravenous ImmunoglobulinScandinavian Journal of Rheumatology, 1996
- Treatment of Hemolytic Anemia and Severe Thrombocytopenia with Highdose Methylprednisolone and Intravenous Immunoglobulins in SLEScandinavian Journal of Rheumatology, 1994
- Treatment of Systemic Lupus erythematosus-Associated Thrombocytopenia with Intravenous Gamma GlobulinNephron, 1994
- Pure Red Cell Aplasia Associated with Systemic Lupus erythematosus: Remission after a Single Course of Intravenous ImmunoglobulinActa Haematologica, 1993
- Improvement of Histological and Immunological Change in Steroid and Immunosuppressive Drug-Resistant Lupus nephritis by High-Dose Intravenous Gamma GlobulinNephron, 1989